Glucose metabolism and antidepressant medication

Current Pharmaceutical Design

Volumn 18, Issue 32, 2012, Pages 5900-5919

  Hennings, Johannes M ^a   Schaaf, Ludwig ^a   Fulda, Stephany ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Antidepressants; Depression; Glucose metabolism; Glucose tolerance; Glycemic control; Insulin; Insulin resistance; Insulin sensitivity

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; FLUOXETINE; HEMOGLOBIN A1C; IMIPRAMINE; INSULIN; INTERLEUKIN 1; INTERLEUKIN 6; IPRONIAZID; ISOCARBOXAZID; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NIALAMIDE; NORADRENALIN; NORTRIPTYLINE; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; STRESS HORMONE; TIANEPTINE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VENLAFAXINE; CLOMIPRAMINE; DOXEPIN; ESCITALOPRAM; GLUCOSE; HYDRAZINE DERIVATIVE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

BODY WEIGHT; DEPRESSION; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOOD; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETIC NEUROPATHY; DIET THERAPY; DRUG MECHANISM; HIGH RISK PATIENT; IMPAIRED GLUCOSE TOLERANCE; MIGRAINE; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; POSTTRAUMATIC STRESS DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEDATION; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT GAIN;

ANIMALS; ANTIDEPRESSIVE AGENTS; BLOOD GLUCOSE; BRAIN; DEPRESSION; FEMALE; GLUCOSE METABOLISM DISORDERS; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; MALE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84867713242     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803523662     Document Type: Review

References (184)

1. McCowan PK, Quastel JH. Blood-Sugar Studies in Abnormal Mental States. Br J Psychiatry 1931; 77: 525-548.
2. Allers R. Ergebnisse stoffwechselpathologischer Untersuchungen bei Psychosen. III. Das manisch-depressive Irresein. Z ges Neurol Psychiat 1914; 9: 585.
3. Kooy FH. Hyperglycaemia in mental disorders. Brain 1919; 42: 214.
4. Pryce IG. Melancholia, glucose tolerance and body weight. J Ment Sci 1958; 104: 421-7.
5. Winokur A, Maislin G, Phillips JL, Amsterdam JD. Insulin resistance after oral glucose tolerance testing in patients with major depression. Am J Psychiatry 1988; 145: 325-30.
6. Wright JH, Jacisin JJ, Radin NS, Bell RA. Glucose metabolism in unipolar depression. Br J Psychiatry 1978; 132: 386-93.
7. Freeman H. Resistance to insulin in mentally disturbed soldiers. Arch Neurol Psychiatry 1946; 56: 74-8.
8. Herzberg B, Coppen A, Marks V. Glucose tolerance in depression. Br J Psychiatry 1968; 114: 627-30.
9. Mueller PS, Heninger GR, McDonald RK. Insulin tolerance test in depression. Arch Gen Psychiatry 1969; 21: 587-94.
10. Mueller PS, Heninger GR, McDonald RK. Intravenous glucose tolerance test in depression. Arch Gen Psychiatry 1969; 21: 470-7.
11. Aksel IS. [The antidepressive drugs and their effect on glucose metabolism]. Wien Med Wochenschr 1960; 110: 713-4.
12. van Praag H, Leijnse B. [The effect of antidepressive agents of the hydrazine type on carbohydrate metabolism in depressive patients]. Ned Tijdschr Geneeskd 1964; 108: 1935-40.
13. van Praag HM, Leijnse B. Depression, glucose tolerance, peripheral glucose uptake and their alterations under the influence of antidepressive drugs of the hydrazine type. Psychopharmacologia 1965; 8: 67-78.
14. Kaplan SM, Mass JW, Pixley JM, Ross WD. Use of imipramine in diabetics. Effects on glycosuria and blood sugar levels. JAMA 1960; 174: 511-7.
15. McIntyre RS, Park KY, Law CWY, et al. The association between conventional antidepressants and the metabolic syndrome: a reviewof the evidence and clinical implications. CNS Drugs 2010; 24: 741-53.
16. Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166: 591-8.
17. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006; 5: 157-68.
18. Crucitti A, Zhang Q, Nilsson M, Brecht S, Yang CR, Wernicke J. Duloxetine treatment and glycemic controls in patients with diagnoses other than diabetic peripheral neuropathic pain: a metaanalysis. Curr Med Res Opin 2010; 26: 2579-88.
19. Pollak PT, Mukherjee SD, Fraser AD. Sertraline-induced hypoglycemia. Ann Pharmacother 2001; 35: 1371-4.
20. Khoza S, Barner JC. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. Int J Clin Pharm 2011; 33: 484-92.
21. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002; 10: 633-41.
22. Nakra BR, Rutland P, Verma S, Gaind R. Amitriptyline and weight gain: a biochemical and endocrinological study. Curr Med Res Opin 1977; 4: 602-6.
23. Catalano MC, Catalano G, Kanfer SN, Toner LC, Stock SL, Taylor WD. The effect of sertraline on routine blood chemistry values. Clin Neuropharmacol 2000; 23: 267-70.
24. Ljung T, Ahlberg AC, Holm G, et al. Treatment of abdominally obese men with a serotonin reuptake inhibitor: a pilot study. J Intern Med 2001; 250: 219-24.
25. Langer G, Karobath M, Sieghart W, Aschauer H, Placheta P, Spona J. Effects of antidepressant treatment with clomipramine on hormonal responses to thyrotropin-releasing hormone and insulininduced hypoglycemia: implications for the "monoaminehypothesis." Pharmacopsychiatria 1981; 14: 100-6.
26. Berilgen MS, Bulut S, Gonen M, Tekatas A, Dag E, Mungen B. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia 2005; 25: 1048-53.
27. Knol MJ, Twisk JWR, Beekman ATF, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia 2006; 49: 837-45.
28. Goodnick PJ, Henry JH, Buki VM. Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry 1995; 56: 128-36.
29. Gavard JA, Lustman PJ, Clouse RE. Prevalence of depression in adults with diabetes. An epidemiological evaluation. Diabetes Care 1993; 16: 1167-78.
30. Lustman PJ, Griffith LS, Freedland KE, Clouse RE. The course of major depression in diabetes. Gen Hosp Psychiatry 1997; 19: 138-43.
31. Marcus MD, Wing RR, Guare J, Blair EH, Jawad A. Lifetime prevalence of major depression and its effect on treatment outcome in obese type II diabetic patients. Diabetes Care 1992; 15: 253-5.
32. Knol MJ, Derijks HJ, Geerlings MI, et al. Influence of antidepressants on glycaemic control in patients with diabetes mellitus. Pharmacoepidemiol Drug Saf 2008; 17: 577-86.
33. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-46.
34. Matsuda M. Measuring and estimating insulin resistance in clinical and research settings. Nutr Metab Cardiovasc Dis 2010; 20: 79-86.
35. Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 1999; 48: 2197-203.
36. Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in noninsulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 707-13.
37. Bartoli E, Fra GP, Carnevale Schianca GP. The oral glucose tolerance test (OGTT) revisited. Eur J Intern Med 2011; 22: 8-12.
38. Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000; 23: 295-301.
39. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-70.
40. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 Suppl 1: S62-69.
41. Malkani S, Mordes JP. Implications of using hemoglobin A1C for diagnosing diabetes mellitus. Am J Med 2011; 124: 395-401.
42. Fajans SS, Herman WH, Oral EA. Insufficient sensitivity of hemoglobin A(_C) determination in diagnosis or screening of early diabetic states. Metab Clin Exp 2011; 60: 86-91.
43. WHO Collaboration Centre for Drugs Statistics Methodology. ATC/DDD index 2011 [online]. Available at: http://www.whocc.no/atc_ddd_index/.
44. Wójcikiewicz O, Szopińska-Ciba L. [Effect of nuredal on carbohydrate metabolism in diabetes mellitus]. Pol Tyg Lek 1970; 25: 97-9.
45. van Praag H, Leijnse B. The influence of some antidepressives of the hydrazine type on the glucose metabolism in depressed patients. Clin Chim Acta 1963; 8: 466-75.
46. van Praag H, Leijnse B. The xylose metabolism in depressed patients and its alterations under the influence of antidepressive hydrazines. Clin Chim Acta 1965; 11: 13-23.
47. Parodi F. [On the antidiabetic effect of phenelzine]. Clin Ter 1967; 42: 443-8.
48. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340: 249-58.
49. Heninger GR, Mueller PS, Davis LS. Depressive symptoms and the glucose tolerance test and insulin tolerance test. J Nerv Ment Dis 1975; 161: 421-32.
50. Weber-Hamann B, Gilles M, Lederbogen F, Heuser I, Deuschle M. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry 2006; 67: 1856-61.
51. Sindrup SH, Tuxen C, Gram LF, et al. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol 1992; 43: 251-5.
52. Moosa MYH, Panz VR, Jeenah FY, Joffe BI. African women with depression: the effect of imipramine and fluoxetine on body mass index and leptin secretion. J Clin Psychopharmacol 2003; 23: 549-52.
53. Ghaeli P, Shahsavand E, Mesbahi M, Kamkar MZ, Sadeghi M, Dashti-Khavidaki S. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. J Clin Psychopharmacol 2004; 24: 386-8.
54. Kathol RG, Jaeckle R, Wysham C, Sherman BM. Imipramine effect on hypothalamic-pituitary-adrenal axis response to hypoglycemia. Psychiatry Res 1992; 41: 45-52.
55. Lechin F, van der Dijs B, Lechin A, et al. Doxepin therapy for postprandial symptomatic hypoglycaemic patients: neurochemical, hormonal and metabolic disturbances. Clin Sci 1991; 80: 373-84.
56. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005; 10: 732-47.
57. Abrahamian H, Hofmann P, Prager R, Toplak H. Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group). Neuropsychiatr Dis Treat 2009; 5: 261-6.
58. Weber-Hamann B, Gilles M, Schilling C, et al. Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine. J Clin Psychopharmacol 2008; 28: 581-4.
59. Chen YC, Lin WW, Chen YJ, Mao WC, Hung YJ. Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males. Mediators Inflamm 2010; 2010: 573-94.
60. Hall JA, Wang F, Oakes TMM, Utterback BG, Crucitti A, Acharya N. Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials. Expert Opin Drug Saf 2010; 9: 525-37.
61. Jezová D, Duncko R. Enhancement of stress-induced pituitary hormone release and cardiovascular activation by antidepressant treatment in healthy men. J Psychopharmacol (Oxford) 2002; 16: 235-40.
62. Kamarck TW, Muldoon MF, Manuck SB, et al. Citalopram improves metabolic risk factors among high hostile adults: results of a placebo-controlled intervention. Psychoneuroendocrinology 2011; 36: 1070-9.
63. Khazaie H, Rahimi M, Tatari F, Rezaei M, Najafi F, Tahmasian M. Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram? Neurosciences (Riyadh) 2011; 16: 42-5.
64. Everson-Rose SA, Lewis TT. Psychosocial factors and cardiovascular diseases. Annu Rev Public Health 2005; 26: 469-500.
65. Kauffman RP, Castracane VD, White DL, Baldock SD, Owens R. Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age. Gynecol Endocrinol 2005; 21: 129-37.
66. Paile-Hyvärinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Pract 2003; 4: 7.
67. Paile-Hyvärinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial. BMC Fam Pract 2007; 8: 34.
68. Goodnick PJ, Kumar A, Henry JH, Buki VM, Goldberg RB. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacol Bull 1997; 33: 261-4.
69. Echeverry D, Duran P, Bonds C, Lee M, Davidson MB. Effect of pharmacological treatment of depression on A1C and quality of life in low-income Hispanics and African Americans with diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2009; 32: 2156-60.
70. Komorousova J, Beran J, Rusavy Z, Jankovec Z. Glycemic control improvement through treatment of depression using antidepressant drugs in patients with diabetes mellitus type 1. Neuro Endocrinol Lett 2010; 31: 801-6.
71. Lustman PJ, Clouse RE, Nix BD, et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, doubleblind, placebo-controlled trial. Arch Gen Psychiatry 2006; 63: 521-9.
72. Briscoe VJ, Ertl AC, Tate DB, Dawling S, Davis SN. Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycemia in healthy individuals. Diabetes 2008; 57: 2453-60.
73. Visser M, Seidell JC, Koppeschaar HP, Smits P. No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obes Res 1994; 2: 152-9.
74. Bondi M, Menozzi R, Bertolini M, Venneri MG, Del Rio G. Metabolic effects of fluoxetine in obese menopausal women. J Endocrinol Invest 2000; 23: 280-6.
75. Guimarães C, Pereira LRL, Iucif Júnior N, et al. Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients. Arq Bras Endocrinol Metabol 2006; 50: 1020-5.
76. Chen YC, Shen YC, Hung YJ, Chou CH, Yeh CB, Perng CH. Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. J Affect Disord 2007; 103: 257-61.
77. Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebocontrolled trial. Diabetes Care 2000; 23: 618-23.
78. Gülseren L, Gülseren S, Hekimsoy Z, Mete L. Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients. Arch Med Res 2005; 36: 159-65.
79. Briscoe VJ, Ertl AC, Tate DB, Davis SN. Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes. Diabetes 2008; 57: 3315-22.
80. Potter van Loon BJ, Radder JK, Frölich M, Krans HM, Zwinderman AH, Meinders AE. Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals. Int J Obes Relat Metab Disord 1992; 16: 79-85.
81. Maheux P, Ducros F, Bourque J, Garon J, Chiasson JL. Fluoxetine improves insulin sensitivity in obese patients with non-insulindependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 1997; 21: 97-102.
82. O'Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994; 11: 105-10.
83. Daubresse JC, Kolanowski J, Krzentowski G, Kutnowski M, Scheen A, Van Gaal L. Usefulness of fluoxetine in obese noninsulin-dependent diabetics: a multicenter study. Obes Res 1996; 4: 391-6.
84. Gray DS, Fujioka K, Devine W, Bray GA. Fluoxetine treatment of the obese diabetic. Int J Obes Relat Metab Disord 1992; 16: 193-8.
85. Kutnowski M, Daubresse JC, Friedman H, et al. Fluoxetine therapy in obese diabetic and glucose intolerant patients. Int J Obes Relat Metab Disord 1992; 16 Suppl 4: S63-66.
86. Breum L, Bjerre U, Bak JF, Jacobsen S, Astrup A. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metab Clin Exp 1995; 44: 1570-6.
87. Connolly VM, Gallagher A, Kesson CM. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabet Med 1995; 12: 416-8.
88. Karabacak IYNI, Karabacak O, Törüner FB, Akdemir O, Arslan M. Treatment effect of sibutramine compared to fluoxetine on leptin levels in polycystic ovary disease. Gynecol Endocrinol 2004; 19: 196-201.
89. Ye Z, Chen L, Yang Z, et al. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. PLoS ONE 2011; 6: e21551.
90. Araya V, Contreras P, Aguirre C, Depix MS, Zura ML. [The effect of fluoxetine on insulin resistance in non diabetic obese patients]. Rev Med Chil 1995; 123: 943-7.
91. Burrows GD, Maguire KP, Norman TR. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 1998; 59 Suppl 14: 4-7.
92. Paslakis G, Gilles M, Lederbogen F, Schilling C, Scharnholz B, Deuschle M. The effect of a 4-week treatment with reboxetine on metabolic parameters of depressed inpatients. Eur Arch Psychiatry Clin Neurosci 2011; 261: 173-7.
93. Talaei A, Siavash M, Majidi H, Chehrei A. Vitamin B12 may be more effective than nortriptyline in improving painful diabetic neuropathy. Int J Food Sci Nutr 2009; 60 Suppl 5: 71-6.
94. Pinar M, Gulsun M, Tasci I, et al. Maprotiline induced weight gain in depressive disorder: changes in circulating ghrelin and adiponectin levels and insulin sensitivity. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 135-9.
95. Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a doubleblind, placebo-controlled trial. Psychosom Med 1997; 59: 241-50.
96. Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002; 10: 1049-56.
97. Lustman PJ, Williams MM, Sayuk GS, Nix BD, Clouse RE. Factors influencing glycemic control in type 2 diabetes during acuteand maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care 2007; 30: 459-66.
98. Efstathiou SP, Skeva II, Dimas C, et al. Smoking cessation increases serum adiponectin levels in an apparently healthy Greek population. Atherosclerosis 2009; 205: 632-6.
99. Szegedi A, Schwertfeger N. Mirtazapine: a review of its clinical efficacy and tolerability. Expert Opin Pharmacother 2005; 6: 631-41.
100. Haddjeri N, Blier P, de Montigny C. Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission. J Affect Disord 1998; 51: 255-66.
101. Radhakishun FS, van den Bos J, van der Heijden BC, Roes KC, O'Hanlon JF. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol 2000; 20: 531-7.
102. Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmächer T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002; 35: 220-5.
103. Nicholas LM, Ford AL, Esposito SM, Ekstrom RD, Golden RN. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry 2003; 64: 883-9.
104. Himmerich H, Fulda S, Schaaf L, Beitinger PA, Schuld A, Pollmächer T. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care 2006; 29: 170.
105. Laimer M, Kramer-Reinstadler K, Rauchenzauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry 2006; 67: 421-4.
106. Alderman CP, Condon JT, Gilbert AL. An open-label study of mirtazapine as treatment for combat-related PTSD. Ann Pharmacother 2009; 43: 1220-6.
107. Goodnick PJ, Breakstone K, Kumar A, Freund B, DeVane CL. Nefazodone in diabetic neuropathy: response and biology. Psychosom Med 2000; 62: 599-600.
108. Bressler R, Johnson D. New pharmacological approaches to therapy of NIDDM. Diabetes Care 1992; 15: 792-805.
109. Haeckel R, Oellerich M. Hydrazonopropionic acids, a new class of non-hormonal hypoglycaemic compounds. Biochem Soc Trans 1979; 7: 749-52.
110. Boschmann M, Schroeder C, Christensen NJ, et al. Norepinephrine transporter function and autonomic control of metabolism. J Clin Endocrinol Metab 2002; 87: 5130-7.
111. Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 2001; 13: 31-41.
112. Fagerholm V, Haaparanta M, Scheinin M. α(2)-Adrenoceptor Regulation of Blood Glucose Homeostasis. Basic Clin Pharmacol Toxicol 2011; 108: 365-70.
113. Erenmemisoglu A, Ozdogan UK, Saraymen R, Tutus A. Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hyperglycaemic mice. J Pharm Pharmacol 1999; 51: 741-3.
114. Buse MG, Johnson AH, Kuperminc D, Buse J. Effect of alphaadrenergic blockade on insulin secretion in man. Metab Clin Exp 1970; 19: 219-25.
115. Kawazu S, Suzuki M, Negishi K, Watanabe T, Ishii J. Studies of midaglizole (DG-5128). A new type of oral hypoglycemic drug in healthy subjects. Diabetes 1987; 36: 216-20.
116. Ortiz-Alonso FJ, Herman WH, Gertz BJ, Williams VC, Smith MJ, Halter JB. Effect of an oral alpha 2-adrenergic blocker (MK-912) on pancreatic islet function in non-insulin-dependent diabetes mellitus. Metab Clin Exp 1991; 40: 1160-7.
117. Kawazu S, Suzuki M, Negishi K, et al. Initial phase II clinical studies on midaglizole (DG-5128). A new hypoglycemic agent. Diabetes 1987; 36: 221-6.
118. Robertson RP, Halter JB, Porte D Jr. A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus. J Clin Invest 1976; 57: 791-5.
119. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996; 57 Suppl 4: 19-25.
120. Wilson GA, Furman BL. Effects of inhibitors of 5-hydroxytryptamine uptake on plasma glucose and their interaction with 5-hydroxytryptophan in producing hypoglycaemia in mice. Eur J Pharmacol 1982; 78: 263-70.
121. Furman BL. The hypoglycaemic effect of 5-hydroxytryptophan. Br J Pharmacol 1974; 50: 575-80.
122. Yamada J, Sugimoto Y, Inoue K. Selective serotonin reuptake inhibitors fluoxetine and fluvoxamine induce hyperglycemia by different mechanisms. Eur J Pharmacol 1999; 382: 211-5.
123. Dryden S, Frankish HM, Wang Q, Pickavance L, Williams G. The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats. Neuroscience 1996; 72: 557-66.
124. Gomez R, Huber J, Lhullier F, Barros HM. Plasma insulin levels are increased by sertraline in rats under oral glucose overload. Braz J Med Biol Res 2001; 34: 1569-72.
125. Giorgetti M, Tecott LH. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur J Pharmacol 2004; 488: 1-9.
126. Pestell RG, Crock PA, Ward GM, Alford FP, Best JD. Fenfluramine increases insulin action in patients with NIDDM. Diabetes Care 1989; 12: 252-8.
127. Scheen AJ, Paolisso G, Salvatore T, Lefèbvre PJ. Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine. Diabetes Care 1991; 14: 325-32.
128. Greco AV, Mingrone G, Capristo E, De Gaetano A, Ghirlanda G, Castagneto M. Effects of dexfenfluramine on free fatty acid turnover and oxidation in obese patients with type 2 diabetes mellitus. Metab Clin Exp 1995; 44: 57-61.
129. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord 1997; 21 Suppl 1: S25-29.
130. Marston OJ, Heisler LK. Targeting the serotonin 2C receptor for the treatment of obesity and type 2 diabetes. Neuropsychopharmacology 34: 252-3.
131. Zhou L, Sutton GM, Rochford JJ, et al. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab 2007; 6: 398-405.
132. Haffner SM. Sex hormone-binding protein, hyperinsulinemia, insulin resistance and noninsulin-dependent diabetes. Horm Res 1996; 45: 233-7.
133. Lustman PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998; 129: 613-21.
134. Kelley DE, Goodpaster BH. Effects of physical activity on insulin action and glucose tolerance in obesity. Med Sci Sports Exerc 1999; 31: S619-623.
135. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67: 220-9.
136. Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management. Diab Vasc Dis Res 2005; 2: 9-15.
137. Hales CN, Randle PJ. Effects of low-carbohydrate diet and diabetes mellitus on plasma concentrations of glucose, non-esterified fatty acid, and insulin during oral glucose-tolerance tests. Lancet 1963; 1: 790-4.
138. Lingjaerde O. Failure in the utilization of carbohydrates in mental disease. Acta Psychiatr Neurol Scand Suppl 1956; 106: 302-10.
139. Green JG, Johnson NA, Sachinwalla T, Cunningham CW, Thompson MW, Stannard SR. Low-carbohydrate diet does not affect intramyocellular lipid concentration or insulin sensitivity in lean, physically fit men when protein intake is elevated. Metab Clin Exp 2010; 59: 1633-41.
140. Webber J, Simpson E, Parkin H, Macdonald IA. Metabolic effects of acute hyperketonaemia in man before and during an hyperinsulinaemic euglycaemic clamp. Clin Sci 1994; 86: 677-87.
141. Mansell PI, Macdonald IA. The effect of starvation on insulininduced glucose disposal and thermogenesis in humans. Metab Clin Exp 1990; 39: 502-10.
142. Scheen AJ, Castillo M, Lefèbvre PJ. Insulin sensitivity in anorexia nervosa: a mirror image of obesity? Diabetes Metab Rev 1988; 4: 681-90.
143. Wyshak GH, Chaikof IL. Metabolic defects in the liver of fasted rats as shown by utilization of C14-labeled glucose and fructose. J Biol Chem 1953; 200: 851-7.
144. Weil-Malherbe H. The concentration of adrenaline in human plasma and its relation to mental activity. J Ment Sci 1955; 101: 733-55.
145. Johnson NA, Stannard SR, Rowlands DS, et al. Effect of shortterm starvation versus high-fat diet on intramyocellular triglyceride accumulation and insulin resistance in physically fit men. Exp Physiol 2006; 91: 693-703.
146. Fukushima M, Nakai Y, Taniguchi A, Imura H, Nagata I, Tokuyama K. Insulin sensitivity, insulin secretion, and glucose effectiveness in anorexia nervosa: a minimal model analysis. Metab Clin Exp 1993; 42: 1164-8.
147. Hermans MP, Lambert MJ. HOMA-modelling of insulin sensitivity and β-cell function in anorexia nervosa. European Eating Disorders Review 2002; 10: 41-50.
148. Adam-Perrot A, Clifton P, Brouns F. Low-carbohydrate diets: nutritional and physiological aspects. Obes Rev 2006; 7: 49-58.
149. Weber B, Schweiger U, Deuschle M, Heuser I. Major depression and impaired glucose tolerance. Exp Clin Endocrinol Diabetes 2000; 108: 187-90.
150. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501.
151. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000; 57: 925-35.
152. McEwen BS. Mood disorders and allostatic load. Biol Psychiatry 2003; 54: 200-7.
153. Brown ES, Varghese FP, McEwen BS. Association of depression with medical illness: does cortisol play a role? Biol Psychiatry 2004; 55: 1-9.
154. Ising M, Künzel HE, Binder EB, Nickel T, Modell S, Holsboer F. The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1085-93.
155. Ising M, Horstmann S, Kloiber S, et al. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression-a potential biomarker? Biol Psychiatry 2007; 62: 47-54.
156. Hennings JM, Owashi T, Binder EB, et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients-findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009; 43: 215-29.
157. Hennings JM, Ising M, Grautoff S, Himmerich H, Pollmächer T, Schaaf L. Glucose tolerance in depressed inpatients, under treatment with mirtazapine and in healthy controls. Exp Clin Endocrinol Diabetes 2010; 118: 98-100.
158. Himmerich H, Fulda S, Linseisen J, et al. Depression, comorbidities and the TNF-alpha system. Eur Psychiatry 2008; 23: 421-9.
159. Himmerich H, Binder EB, Künzel HE, et al. Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol Psychiatry 2006; 60: 882-8.
160. Dinan TG. Inflammatory markers in depression. Curr Opin Psychiatry 2009; 22: 32-6.
161. Pyter LM, Pineros V, Galang JA, McClintock MK, Prendergast BJ. Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic-pituitary-adrenal axis regulation. Proc Natl Acad Sci USA 2009; 106: 9069-74.
162. Raedler TJ. Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry 2011; 24: 519-25.
163. Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am 2009; 29: 247-64.
164. Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord 2000; 24 Suppl 4: S23-27.
165. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003; 278: 13740-6.
166. Lehto SM, Huotari A, Niskanen L, et al. Serum adiponectin and resistin levels in major depressive disorder. Acta Psychiatr Scand 2010; 121: 209-15.
167. Narita K, Murata T, Takahashi T, Kosaka H, Omata N, Wada Y. Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1159-62.
168. Hinze-Selch D, Schuld A, Kraus T, et al. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 2000; 23: 13-9.
169. Hannestad J, Dellagioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: A meta-analysis. Neuropsychopharmacology 2011; in press.
170. Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG. Cutaneous glucocorticoid receptor sensitivity and proinflammatory cytokine levels in antidepressant-resistant depression. Psychol Med 2006; 36: 37-43.
171. O'Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 2004; 19: 397-403.
172. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109-18.
173. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6: 346-56.
174. Wernicke JF, Raskin J, Rosen A, et al. Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An openlabel, 52-week extension of a randomized controlled clinical trial. Curr Ther Res Cllin Exp 2006; 67: 283-304.
175. Perahia DGS, Maina G, Thase ME, et al. Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 706-16.
176. Skljarevski V, Zhang S, Chappell AS, Walker DJ, Murray I, Backonja M. Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study. Pain Med 2010; 11: 648-57.
177. Chappell AS, Bradley LA, Wiltse C, Detke MJ, D'Souza DN, Spaeth M. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 2009; 1: 91-102.
178. Hartford J, Kornstein S, Liebowitz M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007; 22: 167-74.
179. Koponen H, Allgulander C, Erickson J, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 2007; 9: 100-7.
180. Nicolini H, Bakish D, Duenas H, et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extendedrelease and placebo-controlled trial. Psychol Med 2009; 39: 267-76.
181. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008; 136: 432-44.
182. Rynn M, Russell J, Erickson J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexibledose, progressive-titration, placebo-controlled trial. Depress Anxiety 2008; 25: 182-9.
183. Skljarevski V, Ossanna M, Liu-Seifert H, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 2009; 16: 1041-8.
184. Amsterdam JD, Shults J, Rutherford N, Schwartz S. Safety and efficacy of s-citalopram in patients with co-morbid major depression and diabetes mellitus. Neuropsychobiology 2006; 54: 208-14. Received: May